These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15497329)

  • 1. [Selective estrogen receptor modulators].
    Holzgrabe U
    Pharm Unserer Zeit; 2004; 33(5):357-9. PubMed ID: 15497329
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions.
    Jordan VC
    J Med Chem; 2003 Mar; 46(6):883-908. PubMed ID: 12620065
    [No Abstract]   [Full Text] [Related]  

  • 3. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents.
    Jordan VC
    J Med Chem; 2003 Mar; 46(7):1081-111. PubMed ID: 12646017
    [No Abstract]   [Full Text] [Related]  

  • 4. The science of selective estrogen receptor modulators: concept to clinical practice.
    Jordan VC
    Clin Cancer Res; 2006 Sep; 12(17):5010-3. PubMed ID: 16951214
    [No Abstract]   [Full Text] [Related]  

  • 5. [Selective estrogen receptor modulators: mechanisms of action and their tissue selectivity].
    Azuma K; Inoue S
    Clin Calcium; 2004 Oct; 14(10):12-26. PubMed ID: 15577127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The molecular perspective: tamoxifen and the estrogen receptor.
    Goodsell DS
    Stem Cells; 2002; 20(3):267-8. PubMed ID: 12004085
    [No Abstract]   [Full Text] [Related]  

  • 7. Oestrogen receptors and selective oestrogen receptor modulators: molecular and cellular pharmacology.
    Nilsson S; Koehler KF
    Basic Clin Pharmacol Toxicol; 2005 Jan; 96(1):15-25. PubMed ID: 15667591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective estrogen-receptor modulators for primary prevention of breast cancer.
    Fabian CJ; Kimler BF
    J Clin Oncol; 2005 Mar; 23(8):1644-55. PubMed ID: 15755972
    [No Abstract]   [Full Text] [Related]  

  • 9. An issue of tissues: divining the split personalities of selective estrogen receptor modulators.
    McKenna NJ; O'Malley BW
    Nat Med; 2000 Sep; 6(9):960-2. PubMed ID: 10973303
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of two novel selective estrogen receptor modulators, raloxifene, tamoxifen, and ethinyl estradiol on the uterus, vagina and breast in ovariectomized cynomolgus monkeys (Macaca fascicularis).
    Sikoski P; Register TC; Lees CJ; Lundeen S; Hutchison J; Brown KH; Cline JM
    Am J Obstet Gynecol; 2007 Jan; 196(1):75.e1-7. PubMed ID: 17240242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Selective estrogen receptors modulators (SERMs): biochemistry, pharmacology, and clinical use in gynecology].
    Terán Dávila J; Teppa Garrán AD
    Ginecol Obstet Mex; 2005 Aug; 73(8):424-35. PubMed ID: 16304968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen receptor ligands. Part 8: Dihydrobenzoxathiin SERAMs with heteroatom-substituted side chains.
    Blizzard TA; DiNinno F; Morgan JD; Wu JY; Chen HY; Kim S; Chan W; Birzin ET; Yang YT; Pai LY; Zhang Z; Hayes EC; DaSilva CA; Tang W; Rohrer SP; Schaeffer JM; Hammond ML
    Bioorg Med Chem Lett; 2004 Aug; 14(15):3865-8. PubMed ID: 15225686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen receptor ligands. Part 13: Dihydrobenzoxathiin SERAMs with an optimized antagonist side chain.
    Blizzard TA; DiNinno F; Chen HY; Kim S; Wu JY; Chan W; Birzin ET; Yang YT; Pai LY; Hayes EC; DaSilva CA; Rohrer SP; Schaeffer JM; Hammond ML
    Bioorg Med Chem Lett; 2005 Sep; 15(17):3912-6. PubMed ID: 15993065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advantages of multiple clinical tests for determining the optimum treatment strategy for ER-positive breast cancer.
    Ditzel HJ; Lyng MB
    Nat Clin Pract Oncol; 2008 Jul; 5(7):376-7. PubMed ID: 18506164
    [No Abstract]   [Full Text] [Related]  

  • 15. m-Carborane bisphenol structure as a pharmacophore for selective estrogen receptor modulators.
    Ogawa T; Ohta K; Yoshimi T; Yamazaki H; Suzuki T; Ohta S; Endo Y
    Bioorg Med Chem Lett; 2006 Aug; 16(15):3943-6. PubMed ID: 16735120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. QSAR of estrogen receptor modulators: exploring selectivity requirements for ER(alpha) versus ER(beta) binding of tetrahydroisoquinoline derivatives using E-state and physicochemical parameters.
    Mukherjee S; Saha A; Roy K
    Bioorg Med Chem Lett; 2005 Feb; 15(4):957-61. PubMed ID: 15686893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.
    Jain N; Xu J; Kanojia RM; Du F; Jian-Zhong G; Pacia E; Lai MT; Musto A; Allan G; Reuman M; Li X; Hahn D; Cousineau M; Peng S; Ritchie D; Russell R; Lundeen S; Sui Z
    J Med Chem; 2009 Dec; 52(23):7544-69. PubMed ID: 19366247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators.
    McDonnell DP; Connor CE; Wijayaratne A; Chang CY; Norris JD
    Recent Prog Horm Res; 2002; 57():295-316. PubMed ID: 12017549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bringing estrogen receptors under control.
    Horwitz KB
    Breast Cancer Res; 1999; 1(1):5-7. PubMed ID: 11250673
    [No Abstract]   [Full Text] [Related]  

  • 20. Selective estrogen receptor modulators: an update on recent clinical findings.
    Shelly W; Draper MW; Krishnan V; Wong M; Jaffe RB
    Obstet Gynecol Surv; 2008 Mar; 63(3):163-81. PubMed ID: 18279543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.